Current strategies for the development of novel antipsychotic drugs
While classical neuroleptics are characterized by dopamine D(2) antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of...
Saved in:
Published in | Mini reviews in medicinal chemistry Vol. 3; no. 3; p. 239 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.05.2003
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | While classical neuroleptics are characterized by dopamine D(2) antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of these new atypical antipsychotics can be classified into three general groups: a) binding to D(2) together with non-dopaminergic receptors, b) interaction with dopamine receptor subtypes other than D(2) and c) selective binding to non-dopaminergic systems, such as glutamatergic, sigma, neurotensin, and cannabinoid. |
---|---|
ISSN: | 1389-5575 |
DOI: | 10.2174/1389557033488169 |